摘要
经历了20余年的发展,抗血管生成治疗已经成为恶性肿瘤的重要治疗手段之一,其与化疗、放疗、表皮生长因子受体(epi-dermal growth factor receptor,EGFR)酪氨酸激酶抑制剂以及免疫药物联合均取得了公认的疗效。但肿瘤微环境治疗药物的特性也使其面临着特有的"瓶颈":如何有效克服其耐药、早期评估疗效、筛选治疗优势人群、将毒性降至最小等。只有阐明这些问题,才能充分发挥其优势,将抗血管生成治疗提升至更高水平。
After a development period of approximately 20 years,anti-angiogenic therapy has now become an important therapeutic tool for neoplasms as it has been shown to have efficacy in combination with chemotherapy,radiotherapy,epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)therapy,and even immunotherapy.However,specific effects of antiangiogenic drugs on the tumor microenvironment lead to specific"bottlenecks"of antiangiogenic therapy.These include the following:how to effectively overcome drug-resistance,how to predict efficacy at an early stage,how to identify the optimal population,and how to diminish toxicity.To fully take advantage of antiangiogenic drugs and to promote their use,these questions need to be answered.
作者
李凯
Kai Li(Department of Thoracic Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Tianjin Key Laboratory of Cancer Prevention and Therapy,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2020年第22期1140-1144,共5页
Chinese Journal of Clinical Oncology
关键词
抗血管生成治疗
耐药
疗效预测
治疗优势人群
antiangiogenic therapy
resistance to drug
prediction of efficacy
therapeutic optimal population
